Prostate cancer diagnostics - new perspectives for salivary and urinary biomarkers
DOI:
https://doi.org/10.12775/JEHS.2025.86.67368Keywords
prostate cancer, liquid biopsy, biomarkers, saliva, precision oncologyAbstract
Background. The growing epidemiological burden of prostate cancer, projected for 2025, combined with the diagnostic limitations of prostate-specific antigen (PSA), necessitates the search for new strategies in precision oncology.
Aim. This review article analyzes the evolution of diagnostic methods, pointing to the need to move from traditional serum markers to non-invasive liquid biopsy.
Material and methods. We synthesize the current state of knowledge on established urinary biomarkers and present a novel approach using saliva as a source of information on cancer status.
Results. The paper discusses the potential of metabolic profiling (sialic acid, citrate), identification of new protein biomarkers (S100P), analysis of specific microRNA signatures depending on the stage of the disease, and the role of the oral microbiome in pathogenesis and risk stratification.
Conclusions. We conclude that salivary and urinary biomarkers represent a rapidly developing experimental direction in prostate cancer diagnostics. Preliminary studies indicate promising diagnostic performance; however, the majority of available evidence is based on pilot and case–control studies and requires further large-scale validation before clinical implementation.
References
[1] Suartz CV, Santos LA, Matalani CFA, DallAqua V, Schumacher LB, Lepine HL, et al. Transperineal Versus Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Genitourin Cancer 2025. https://doi.org/10.1016/j.clgc.2025.102467.
[2] Wang H, Zhao Z, Xu X, Guo Z, Liu G. Ultra-low-dose radioimmunotherapy improves prostate cancer treatment efficacy and safety. Chinese Chemical Letters 2025. https://doi.org/10.1016/j.cclet.2025.111799.
[3] Abramczyk E, Nisar MU, Nguyen JK, Austin N, Ward RD, Weight C, et al. The Role of Prostate-Specific Membrane Antigen-Radioligand and Magnetic Resonance Imaging in Patients with Prostate Cancer Biochemical Recurrence. Seminars in Ultrasound, CT and MRI 2025;46:71–82. https://doi.org/10.1053/J.SULT.2024.11.005.
[4] Li X, Zhang X, Fu X, Wu H, Ye X, Huang X, et al. Urokinase-type plasminogen activator deficiency enhances CD8 + T cell infiltration and anti-PD-1 therapy efficacy in prostate cancer. Front Immunol 2025;16. https://doi.org/10.3389/fimmu.2025.1625226.
[5] Baron D, Pasquier D, Pace-Loscos T, Vandendorpe B, Schiappa R, Ortholan C, et al. Systemic therapy escalation after stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer. Clin Transl Radiat Oncol 2023;43. https://doi.org/10.1016/j.ctro.2023.100673.
[6] Zhao X, Liu S, Zou Z, Liang C. Global, regional, and national prevalence of prostate cancer from 1990 to 2021: a trend and health inequality analyses. Front Public Health 2025;13. https://doi.org/10.3389/fpubh.2025.1595159.
[7] Kessel A, Kohli M, Swami U. Current management of metastatic castration-sensitive prostate cancer. Cancer Treat Res Commun 2021;28:100384. https://doi.org/10.1016/J.CTARC.2021.100384.
[8] Hurlstone A, Black DM. Prostate cancer: New therapies in the pipeline? Current Biology 1998;8. https://doi.org/10.1016/S0960-9822(98)70270-2.
[9] Majd Shokorlou Y, Heidarzadeh H. Multispectral plasmonic biosensors based on a Penta-supercell metamaterial for detection of prostate-specific antigen: Ultrasensitive in LC resonance mode. Biosens Bioelectron 2022;217. https://doi.org/10.1016/j.bios.2022.114722.
[10] Lowes LE, Goodale D, Keeney M, Allan AL. Image Cytometry Analysis of Circulating Tumor Cells. vol. 102. 2011. https://doi.org/10.1016/B978-0-12-374912-3.00010-9.
[11] Tao Z, Shen M, Zheng Y, Mao X, Chen Z, Yin Y, et al. PCA3 gene expression in prostate cancer tissue in a Chinese population: Quantification by real-time FQ-RT-PCR based on exon 3 of PCA3. Exp Mol Pathol 2010;89. https://doi.org/10.1016/j.yexmp.2010.01.008.
[12] Satapathy BS, Mishra A, Behera S, Mohanty M, Kundu AK. Biosensors as emerging tools in cancer theranostics: Recent progress. 2025. https://doi.org/10.1016/B978-0-443-21592-6.00032-X.
[13] Tacke F, Kanig N, En-Nia A, Kaehne T, Eberhardt CS, Shpacovitch V, et al. Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease. BMC Cancer 2011;11. https://doi.org/10.1186/1471-2407-11-185.
[14] Grossfeld GD, Carroll PR, Lindeman N, Meng M, Groshen S, Feng A-C, et al. Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression. Urology 2002;59. https://doi.org/10.1016/S0090-4295(01)01476-5.
[15] O’Hurley G, Busch C, Fagerberg L, Hallström BM, Stadler C, Tolf A, et al. Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer. PLoS One 2015;10. https://doi.org/10.1371/journal.pone.0133449.
[16] Cui Y, Yang M, Zhu J, Zhang H, Duan Z, Wang S, et al. Developments in diagnostic applications of saliva in human organ diseases. Med Nov Technol Devices 2022;13. https://doi.org/10.1016/j.medntd.2022.100115.
[17] Feng K, Ren F, Wang X. Association between oral microbiome and seven types of cancers in East Asian population: a two-sample Mendelian randomization analysis. Front Mol Biosci 2023;10. https://doi.org/10.3389/fmolb.2023.1327893.
[18] Amri J, Goodarzi D, Alaee M, Zarei M, Salehi M. Salivary Biomarkers for Prostate Cancer: A Case-Control Study of PSA and S100P in Iranian Men. Acta Biochimica Iranica 2025. https://doi.org/10.18502/abi.v2i3.19097.
[19] Martin FL, Morais CLM, Dickinson AW, Saba T, Bongers T, Singh MN, et al. Point-of-Care Disease Screening in Primary Care Using Saliva: A Biospectroscopy Approach for Lung Cancer and Prostate Cancer. J Pers Med 2023;13. https://doi.org/10.3390/jpm13111533.
[20] Laidler P, Dulińska J, Lekka M, Lekki J. Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3. Arch Biochem Biophys 2005;435. https://doi.org/10.1016/j.abb.2004.12.003.
[21] Eskicorapci SY, Özkara HA, Önder E, Akdogan B, Erkan İ, Ciliv G, et al. Serum ribonuclease activity in the diagnosis of prostate cancer in men with serum prostate-specific antigen levels between 2.5 and 20 ng/mL. Clin Biochem 2006;39. https://doi.org/10.1016/j.clinbiochem.2005.11.020.
[22] Galey L, Olanrewaju A, Nabi H, Paquette JS, Pouliot F, Audet-Walsh É. PSA, an outdated biomarker for prostate cancer: In search of a more specific biomarker, citrate takes the spotlight. J Steroid Biochem Mol Biol 2024;243:106588. https://doi.org/10.1016/J.JSBMB.2024.106588.
[23] Haider M, Leow JJ, Nordström T, Mortezavi A, Albers P, Heer R, et al. Emerging tools for the early detection of prostate cancer. BJUI Compass 2025;6. https://doi.org/10.1002/bco2.70081.
[24] Gomella LG, Raj G V., Moreno JG. Reverse Transcriptase Polymerase Chain Reaction for Prostate Specific Antigen in the Management of Prostate Cancer. J Urol 1997;158. https://doi.org/10.1016/S0022-5347(01)64472-0.
[25] Iczkowski KA, Bostwick DG. PROSTATE BIOPSY INTERPRETATION: Current Concepts, 1999. Urologic Clinics of North America 1999;26. https://doi.org/10.1016/S0094-0143(05)70193-2.
[26] Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging 2023;50:1466–86. https://doi.org/10.1007/s00259-022-06089-w.
[27] Hohberg M, Kobe C, Krapf P, Täger P, Hammes J, Dietlein F, et al. Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer. EJNMMI Res 2019;9:66. https://doi.org/10.1186/s13550-019-0540-7.
[28] Garg M, Kaur G. Histopathological spectrum of 364 prostatic specimens including immunohistochemistry with special reference to grey zone lesions. Prostate Int 2013;1. https://doi.org/10.12954/PI.13026.
[29] Lima T, Perpétuo L, Henrique R, Fardilha M, Leite-Moreira A, Bastos J, et al. Galectin-3 in prostate cancer and heart diseases: a biomarker for these two frightening pathologies? Mol Biol Rep 2023;50:2763–78. https://doi.org/10.1007/s11033-022-08207-1.
[30] Roobol MJ, Schröder FH, Crawford ED, Freedland SJ, Sartor AO, Fleshner N, et al. A Framework for the Identification of Men at Increased Risk for Prostate Cancer. J Urol 2009;182. https://doi.org/10.1016/j.juro.2009.07.018.
[31] Reynolds MA, Kastury K, Groskopf J, Schalken JA, Rittenhouse H. Molecular markers for prostate cancer. Cancer Lett 2007;249. https://doi.org/10.1016/j.canlet.2006.12.029.
[32] Maimaitiyiming A, An H, Xing C, Li X, Li Z, Bai J, et al. Machine learning-driven mast cell gene signatures for prognostic and therapeutic prediction in prostate cancer. Heliyon 2024;10. https://doi.org/10.1016/j.heliyon.2024.e35157.
[33] Wu D, Ni J, Beretov J, Cozzi P, Willcox M, Wasinger V, et al. Urinary biomarkers in prostate cancer detection and monitoring progression. Crit Rev Oncol Hematol 2017;118:15–26. https://doi.org/10.1016/j.critrevonc.2017.08.002.
[34] Bae J, Yang SH, Kim A, Kim HG. RNA-based biomarkers for the diagnosis, prognosis, and therapeutic response monitoring of prostate cancer. Urologic Oncology: Seminars and Original Investigations 2022;40:105.e1-105.e10. https://doi.org/10.1016/J.UROLONC.2021.11.012.
[35] Mitobe Y, Takayama K ichi, Horie-Inoue K, Inoue S. Prostate cancer-associated lncRNAs. Cancer Lett 2018;418:159–66. https://doi.org/10.1016/J.CANLET.2018.01.012.
[36] Wu M, Zhang X, Han X, Pandey V, Lobie PE, Zhu T. The potential of long noncoding RNAs for precision medicine in human cancer. Cancer Lett 2021;501:12–9. https://doi.org/10.1016/J.CANLET.2020.11.040.
[37] Zhang C, Yang Q, Li W, Kang Y, Zhou F, Chang D. Roles of circRNAs in prostate cancer: Expression, mechanism, application and potential. Int J Biochem Cell Biol 2021;134:105968. https://doi.org/10.1016/J.BIOCEL.2021.105968.
[38] Mahalanobis S, Apoorva, Sharma N, Luthra R, Menon T, Das A. Cancer prognosis and immune system. Microbial Crosstalk with Immune System: New Insights in Therapeutics 2022:75–144. https://doi.org/10.1016/B978-0-323-96128-8.00004-3.
[39] Martignano F, Rossi L, Maugeri A, Gallà V, Conteduca V, De Giorgi U, et al. Urinary RNA-based biomarkers for prostate cancer detection. Clinica Chimica Acta 2017;473:96–105. https://doi.org/10.1016/J.CCA.2017.08.009.
[40] Jain G, Das P, Ranjan P, Neha, Valderrama F, Cieza-Borrella C. Urinary extracellular vesicles miRNA—A new era of prostate cancer biomarkers. Front Genet 2023;14. https://doi.org/10.3389/fgene.2023.1065757.
[41] Liu J, Duan Y. Saliva: A potential media for disease diagnostics and monitoring. Oral Oncol 2012;48. https://doi.org/10.1016/j.oraloncology.2012.01.021.
[42] Trevisan França de Lima L, Müller Bark J, Rasheduzzaman M, Ekanayake Weeramange C, Punyadeera C. Saliva as a matrix for measurement of cancer biomarkers. 2022. https://doi.org/10.1016/B978-0-12-824302-2.00008-4.
[43] Godzien J, López-Gonzálvez Á, García A, Barbas C. Metabolic Phenotyping Using Capillary Electrophoresis Mass Spectrometry. 2019. https://doi.org/10.1016/B978-0-12-812293-8.00005-0.
[44] Farahani H, Alaee M, Amri J, Baghinia MR, Rafiee M. Serum and Saliva concentrations of biochemical parameters in men with prostate cancer and benign prostate hyperplasia. Lab Medicine 2020;51:243–51. https://doi.org/10.1093/LABMED/LMZ053.
[45] Zhang C-Z, Cheng X-Q, Li J-Y, Zhang P, Yi P, Xu X, et al. Saliva in the diagnosis of diseases. Int J Oral Sci 2016;8. https://doi.org/10.1038/ijos.2016.38.
[46] Eftekhari A, Maleki Dizaj S, Sharifi S, Salatin S, Khalilov R, Samiei M, et al. Salivary biomarkers in cancer. vol. 110. 2022. https://doi.org/10.1016/bs.acc.2022.06.005.
[47] Luedemann C, Reinersmann JL, Klinger C, Degener S, Dreger NM, Roth S, et al. Prostate Cancer-Associated miRNAs in Saliva: First Steps to an Easily Accessible and Reliable Screening Tool. Biomolecules 2022;12. https://doi.org/10.3390/biom12101366.
[48] Ahmed SI, Sarwar S, Verma H, Verma R, Lakkireddy C, Adil MAM, et al. Implication of circulating microRNA-21 as a potential non-invasive diagnostic predictor of prostate cancer patients. Human Gene 2022;34:201081. https://doi.org/10.1016/J.HUMGEN.2022.201081.
[49] Nearing JT, DeClercq V, Langille MGI. Investigating the oral microbiome in retrospective and prospective cases of prostate, colon, and breast cancer. NPJ Biofilms Microbiomes 2023;9. https://doi.org/10.1038/s41522-023-00391-7.
[50] Bel’Skaya L V., Sarf EA, Kosenok VK. Analysis of saliva lipids in breast and prostate cancer by IR spectroscopy. Diagnostics 2021;11. https://doi.org/10.3390/diagnostics11081325.
[51] Fernandes B, Roy J, Basuli F, Warner BM, Lindenberg L, Mena E, et al. Salivary excretion of systemically injected [ 18 F]DCFPyL in prostate cancer patients undergoing PSMA scans. Front Oncol 2024;14. https://doi.org/10.3389/fonc.2024.1367962.
[52] Hrebinko R, Taylor SR, Bahnson RR. Carcinoma of prostate metastatic to parotid gland. Urology 1993;41. https://doi.org/10.1016/0090-4295(93)90573-S.
[53] Luedemann C, Reinersmann J-L, Klinger C, Degener S, Dreger NM, Roth S, et al. Correction: Luedemann et al. Prostate Cancer-Associated miRNAs in Saliva: First Steps to an Easily Accessible and Reliable Screening Tool. Biomolecules 2022, 12, 1366. Biomolecules 2023;13:628. https://doi.org/10.3390/biom13040628.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Maciej Łapiński, Monika Lewkowska, Maja Sadowska, Konrad Żochowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 10
Number of citations: 0
